Erudio Healtherudio.com
Sponsor
AbbVie trials: what clinicians said in public
An HCP commentary report on 1 clinical trial sponsored by AbbVie: M21-404. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 29 more trials with public commentary and no report yet.
Listed by lead sponsor as registered on ClinicalTrials.gov (AbbVie; ImmunoGen, Inc.; Pharmacyclics LLC.). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| M21-404 NCT05029882 · AbbVie | advanced solid tumors | Phase 1 | 152 | 62 | Standard | Nov 2, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| MIRASOL NCT04209855 · AbbVie DeepView → | platinum-resistant ovarian cancer with high FRα expression | Phase 3 | Deep | View | |||
| CAPTIVATE NCT02910583 · Pharmacyclics LLC. DeepView → | treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma | Phase 2 | Deep | View | |||
| CANOVA NCT03539744 · AbbVie DeepView → | t(11;14)-positive relapsed or refractory multiple myeloma | Phase 3 | Deep | View | |||
| LUMINOSITY NCT03539536 · AbbVie DeepView → | previously treated c-Met protein-overexpressing, EGFR-wildtype advanced nonsquamous NSCLC | Phase 2 | Deep | View | |||
| SYMPATICO NCT03112174 · Pharmacyclics LLC. DeepView → | relapsed or refractory mantle cell lymphoma | Phase 3 | Deep | View | |||
| CERVINO NCT06158841 · AbbVie DeepView → | relapsed or refractory multiple myeloma | Phase 3 | Deep | View | |||
| TRANSFORM-1 NCT04472598 · AbbVie DeepView → | untreated myelofibrosis | Phase 3 | Deep | View | |||
| GLORIOSA NCT05445778 · AbbVie DeepView → | FRα-high recurrent platinum-sensitive ovarian, fallopian tube, peritoneal cancer | Phase 3 | Deep | View | |||
| SORAYA NCT04296890 · ImmunoGen, Inc. DeepView → | FRα-high platinum-resistant ovarian cancer | Phase 3 | Deep | View | |||
| ReVenG NCT04895436 · AbbVie DeepView → | recurring chronic lymphocytic leukemia | Phase 2 | Deep | View | |||
| VIALE-T NCT04161885 · AbbVie DeepView → | acute myeloid leukemia after allogeneic stem cell transplantation | Phase 3 | Deep | View | |||
| FORWARD I NCT02631876 · ImmunoGen, Inc. StandardView → | folate receptor alpha-positive platinum-resistant epithelial ovarian cancer | Phase 3 | Standard | View | |||
| TRANSFORM-2 NCT04468984 · AbbVie FocusedView → | relapsed/refractory myelofibrosis | Phase 3 | Focused | View | |||
| NCT05599984 NCT05599984 · AbbVie FocusedView → | advanced solid tumors | Phase 1 | Focused | View | |||
| VELIA NCT02470585 · AbbVie FocusedView → | newly diagnosed stage III/IV high-grade serous ovarian cancer | Phase 3 | Focused | View | |||
| NCT02099058 NCT02099058 · AbbVie FocusedView → | advanced solid tumors | Phase 1 | Focused | View | |||
| REFINE NCT03222609 · AbbVie FocusedView → | Not given | Phase 2 | Focused | View | |||
| SEZanne NCT07155174 · AbbVie FocusedView → | previously untreated extensive-stage small cell lung cancer | Phase 2 | Focused | View | |||
| Kilimanjaro NCT05259839 · AbbVie FocusedView → | relapsed/refractory multiple myeloma | Phase 1 | Focused | View | |||
| NCT02899052 NCT02899052 · AbbVie FocusedView → | Not given | Phase 2 | Focused | View | |||
| NCT03386513 NCT03386513 · AbbVie FocusedView → | Not given | Phase 1/Phase 2 | Focused | View | |||
| AndroMETa-CRC NCT07525206 · AbbVie FocusedView → | refractory metastatic colorectal cancer | Phase 3 | Focused | View | |||
| NCT03314181 NCT03314181 · AbbVie FocusedView → | relapsed or refractory multiple myeloma | Phase 2 | Focused | View | |||
| AndroMETa-CRC-064 NCT06614192 · AbbVie FocusedView → | refractory metastatic colorectal cancer expressing c-Met protein | Phase 2 | Focused | View | |||
| NCT07365241 NCT07365241 · AbbVie FocusedView → | relapsed/refractory small cell lung cancer | Phase 3 | Focused | View | |||
| Bellini NCT02755597 · AbbVie FocusedView → | Not given | Phase 3 | Focused | View | |||
| NCT03933735 NCT03933735 · AbbVie FocusedView → | Not given | Phase 1/Phase 2 | Focused | View | |||
| VIALE-M NCT04102020 · AbbVie FocusedView → | Not given | Phase 3 | Focused | View | |||
| NCT06084481 NCT06084481 · AbbVie FocusedView → | Not given | Phase 1 | Focused | View | |||